{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T02:41:26Z","timestamp":1759459286946,"version":"build-2065373602"},"reference-count":19,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2014,4,1]],"date-time":"2014-04-01T00:00:00Z","timestamp":1396310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,4,1]],"date-time":"2014-04-01T00:00:00Z","timestamp":1396310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ajkd.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Kidney Diseases"],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.1053\/j.ajkd.2014.01.010","type":"journal-article","created":{"date-parts":[[2014,1,29]],"date-time":"2014-01-29T11:02:17Z","timestamp":1390993337000},"page":"552-554","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Isn\u2019t It Ironic? Cost-Effectiveness and Willingness to Pay for Tolvaptan in\u00a0the Prevention of Kidney Failure in Autosomal Dominant Polycystic\u00a0Kidney Disease"],"prefix":"10.1053","volume":"63","author":[{"given":"Robert","family":"Nee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina M.","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin C.","family":"Abbott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"24","key":"10.1053\/j.ajkd.2014.01.010_bib1","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1056\/NEJMp1302140","article-title":"Reevaluating \u201cmade in America\u201d\u2014two cost-containment ideas from abroad","volume":"368","author":"Anderson","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.ajkd.2014.01.010_bib2","unstructured":"National Academy of Social Insurance. The future of Medicare. http:\/\/www.nasi.org\/learn\/medicare\/future-medicare. Accessed October 30,\u00a02013."},{"key":"10.1053\/j.ajkd.2014.01.010_bib3","unstructured":"2011 USRDS Annual Report. Vol 2: ESRD, Chapter 11 (Costs of ESRD) p 284. http:\/\/www.usrds.org\/2011\/pdf\/v2_ch011_11.pdf. Accessed October 30,\u00a02013."},{"issue":"3","key":"10.1053\/j.ajkd.2014.01.010_bib4","doi-asserted-by":"crossref","first-page":"174","DOI":"10.7326\/0003-4819-154-3-201102010-00007","article-title":"High-value, cost-conscious health care: concepts for clinicians to evaluate the benefits, harms, and costs of medical interventions","volume":"154","author":"Owens","year":"2011","journal-title":"Ann Intern Med"},{"key":"10.1053\/j.ajkd.2014.01.010_bib5","unstructured":"Accreditation Council for Graduate Medical Education. Program Requirements for Nephrology as of July 2013, IV.A.5.f).(3). www.acgme.org. Accessed January 20, 2014."},{"issue":"1","key":"10.1053\/j.ajkd.2014.01.010_bib6","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s11606-013-2543-9","article-title":"Exploring public attitudes towards approaches to discussing costs in the clinical encounter","volume":"29","author":"Danis","year":"2014","journal-title":"J Gen Intern Med"},{"issue":"6","key":"10.1053\/j.ajkd.2014.01.010_bib7","doi-asserted-by":"crossref","first-page":"382","DOI":"10.7326\/0003-4819-159-6-201309170-00004","article-title":"Cost-effectiveness of tolvaptan in autosomal dominant polycystic kidney disease","volume":"159","author":"Erickson","year":"2013","journal-title":"Ann Intern Med"},{"issue":"25","key":"10.1053\/j.ajkd.2014.01.010_bib8","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","article-title":"Tolvapatan in patients with autosomal dominant polycystic kidney disease","volume":"367","author":"Torres","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"15","key":"10.1053\/j.ajkd.2014.01.010_bib9","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1001\/jama.1996.03540150055031","article-title":"Recommendations of the Panel on Cost-effectiveness in Health and Medicine","volume":"276","author":"Weinstein","year":"1996","journal-title":"JAMA"},{"year":"2001","series-title":"Decision Making in Health and Medicine","author":"Hunink","key":"10.1053\/j.ajkd.2014.01.010_bib10"},{"issue":"1","key":"10.1053\/j.ajkd.2014.01.010_bib11","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3810\/hp.2012.02.942","article-title":"Evaluation of costs associated with tolvaptan-mediated hospital length of stay reduction among US patients with the syndrome of inappropriate antidiuretic hormone secretion, based on SALT-1 and SALT-2 trials","volume":"40","author":"Dasta","year":"2012","journal-title":"Hosp Pract (1995)"},{"issue":"2","key":"10.1053\/j.ajkd.2014.01.010_bib12","first-page":"276","article-title":"Evaluation of costs associated with tolvaptan-mediated length-of-stay reduction among heart failure patients with hyponatremia in the US, based on the EVEREST trial","volume":"15","author":"Chiong","year":"2012","journal-title":"J\u00a0Med Econ"},{"issue":"5","key":"10.1053\/j.ajkd.2014.01.010_bib13","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1530\/EJE-10-1078","article-title":"SALT Investigators. Efficacy and safety of oral tolvaptan therapy in patients with the syndrome of inappropriate antidiuretic hormone secretion","volume":"164","author":"Verbalis","year":"2011","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"10.1053\/j.ajkd.2014.01.010_bib14","doi-asserted-by":"crossref","first-page":"328","DOI":"10.2146\/ajhp100217","article-title":"Effect of serum sodium concentration and tolvaptan treatment on length of hospitalization in patients with heart failure","volume":"68","author":"Cyr","year":"2011","journal-title":"Am J Health Syst Pharm"},{"issue":"2","key":"10.1053\/j.ajkd.2014.01.010_bib15","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMp1305298","article-title":"The gross domestic product and health care spending","volume":"369","author":"Fuchs","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.ajkd.2014.01.010_bib16","unstructured":"Kidney Disease: Improving Global Outcomes. Methods for development of KDIGO practice guidelines. http:\/\/kdigo.org\/home\/guidelines\/development\/. Accessed November 4,\u00a02013."},{"issue":"14","key":"10.1053\/j.ajkd.2014.01.010_bib17","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1056\/NEJMsb050564","article-title":"Medicare and\u00a0cost-effectiveness analysis","volume":"353","author":"Neumann","year":"2005","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1053\/j.ajkd.2014.01.010_bib18","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1177\/0272989X09342277","article-title":"Uncertainty and patient heterogeneity in medical decision models","volume":"30","author":"Groot Koerkamp","year":"2010","journal-title":"Med Decis Making"},{"issue":"1, pt 2","key":"10.1053\/j.ajkd.2014.01.010_bib19","doi-asserted-by":"crossref","first-page":"73","DOI":"10.7326\/0003-4819-156-1-201201031-00001","article-title":"American College of\u00a0Physicians Ethics Manual: sixth edition","volume":"156","author":"Snyder","year":"2012","journal-title":"Ann Intern Med"}],"container-title":["American Journal of Kidney Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638614000195?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638614000195?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T02:20:46Z","timestamp":1759458046000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272638614000195"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4]]},"references-count":19,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,4]]}},"alternative-id":["S0272638614000195"],"URL":"https:\/\/doi.org\/10.1053\/j.ajkd.2014.01.010","relation":{},"ISSN":["0272-6386"],"issn-type":[{"type":"print","value":"0272-6386"}],"subject":[],"published":{"date-parts":[[2014,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Isn\u2019t It Ironic? Cost-Effectiveness and Willingness to Pay for Tolvaptan in\u00a0the Prevention of Kidney Failure in Autosomal Dominant Polycystic\u00a0Kidney Disease","name":"articletitle","label":"Article Title"},{"value":"American Journal of Kidney Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ajkd.2014.01.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}